Greg Weaver

Greg Weaver has extensive work experience in finance and leadership roles in various biotechnology companies.

Greg currently serves as the Chief Financial Officer (CFO) at BioIntelliSense, Inc. since September 2022.

Prior to this, Greg was a Member of the Board of Directors at Atossa Therapeutics starting from May 2014.

From July 2020 to August 2022, they held the position of CFO at atai Life Sciences, where they played a significant role in the company's financial management and strategy.

Before joining atai Life Sciences, Greg was the CFO at Eloxx Pharmaceuticals from October 2017 to March 2020.

Greg also served as the CFO for Prometic Bioproduction Inc. from October 2015 to October 2017, and as a Member of the Board of Directors and Interim CFO at Oryzon from September 2014 to October 2015.

Overall, Greg Weaver has a diverse range of work experience in the biotech industry, particularly in financial management and leadership positions.

Greg Weaver completed their Bachelor of Science degree in Accounting and Finance at Trinity University. Greg'seducational pursuits continued at the Boston College Carroll School of Management, where they obtained a Master of Business Administration (MBA) degree with a focus on Accounting and Finance. The specific duration of their time at Trinity University is not provided.